Schwegman Lundberg & Woessner, P.A.
Anti-PD-L1 antibody
The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.
Fuso Pharmaceutical Industries, Ltd. National University Corporation Hokkaido University
C C C C C A A C A C A C
C12N C07K C07K C07K C12N A61K A61K C07K A61P C07K A61P C07K
inventional additional inventional additional inventional additional additional additional inventional additional inventional additional
Tomohiro Yasuhiko Chie Naoya Asami Kazuhiko Satoru Shiro
Okagawa Suzuki Nakajima Maekawa Nishimori Ohashi Konnai Murata